Common Sites of Thyroid Cancer Metastasis
Thyroid cancer most commonly spreads to the lungs (53%) and bones (28%), with both sites involved in 15% of cases; less common sites include liver (8%), brain (5%), and rarely pancreas, kidney, adrenal glands, and skin. 1
Primary Metastatic Sites
The metastatic pattern differs significantly between thyroid cancer subtypes:
Lungs: The single most frequent site (53.4% of distant metastases) 1
Bones: Second most common (25-28% overall) 1
Combined lung and bone: 15% of metastatic cases 1
Less Common Metastatic Sites
Brain, liver, and skin involvement occurs less frequently but carries significant prognostic implications 1. The research evidence shows:
- Brain metastases (4.7% of cases): Associated with dramatically worse outcomes, with median overall survival of only 5 months 2
- Liver metastases (8.3% of cases): Median survival of 6 months 2
- Pancreas, kidney, adrenal glands, skin: Extremely rare sites 3, 4
Critical Prognostic Considerations
Multi-organ metastatic disease occurs in 26.3% of patients with distant metastases and carries significantly worse prognosis 2. The mortality rate for multiple organ involvement (67.4%) substantially exceeds single organ metastasis (51.2%) 2.
Survival by Metastatic Site:
- Bone metastases: Median OS = 23 months
- Lung metastases: Median OS = 10 months
- Liver metastases: Median OS = 6 months
- Brain metastases: Median OS = 5 months 2
Important Clinical Patterns
Distant metastases occur in fewer than 10% of differentiated thyroid cancer patients overall 1. Half are present at initial diagnosis; the remainder develop later, sometimes decades after initial treatment 1.
Aggressive histological variants show higher metastatic rates, including tall-cell, hobnail, solid, diffuse sclerosing, and columnar-cell variants, particularly when associated with vascular invasion, large primary tumors, extrathyroidal extension, or bulky nodal disease 1.
Common Pitfall to Avoid:
Many patients with bone metastases are asymptomatic at diagnosis 5. Don't rely solely on symptoms to detect metastatic disease—systematic imaging surveillance based on risk stratification is essential.